THE GUT MICROBIOTA FOR HEALTH SUMMIT Madrid, March 7-8, 2020

The gut Microbiome field is moving rapidly and the number of publications increases exponentially impacting basic science research as well as clinical practice in numerous areas. On behalf of the GMFH Scientific Committee, I am happy to invite you to join us in Madrid (Spain) for the ninth annual Gut Microbiota for Health World Summit on March 7 & 8, 2020. The summit is sponsored by the European Society for Neurogastroenterology & Motility (ESNM) and the American Gastroenterological Association (AGA), with the endorsement of the American Neurogastroenterology and Motility Society (ANMS). It will be an excellent occasion to learn about the new discoveries on the role of the gut microbiome in health and diseases and how they are or will be translated to clinical practice for the benefit of health care professionals and patients.

The 2020 program is particularly exciting with the intervention of outstanding international faculty. We will have plenary sessions and workshops dedicated to various aspects including the dietary and non-dietary factors shaping the gut Microbiome, the role of the Gut Microbiome in the modulation of the immune system, Microbiome – drug interactions, gut-brain axis, and fecal microbiota transplantation.

This interdisciplinary scientific program targets a large audience from Microbiome scientists to health care professionals including physicians, nurses, dietitians, and nutritionists.

We look forward to welcoming you to the summit in Madrid!

Harry Sokol, MD PhD Co-Chair of GMFH Scientific Committee

SATURDAY, MARCH 7

08:15 - 08:30 am WELCOME AND DAY 1 KICKOFF Harry Sokol (Paris, France) Fernando Azpiroz (Barcelona, Spain)

08:30 - 09:00 am KEYNOTE LECTURE: TRANSLATING MICROBIOME SCIENCE - REPLACING ROADBLOCKS WITH ROADMAPS Colin Hill (Cork, Ireland)

PLENARY SESSION 1 Dietary and non dietary factors shaping the gut microbiome Session Moderator: Dirk Haller (Munich, Germany)

09:00 - 09:30 am HOST GENETICS Emily Davenport (State College, USA)

09:30 - 10:00 am ENVIRONMENT Eran Segal (Rehovot, Israel)

10:00 - 10:30 am GEOGRAPHY/ IMMIGRATION Ran Blekhman (Minneapolis, USA)

10:30 - 11:00 am Morning Break

PLENARY SESSION 2 Microbiome as orchestrator of the immune system Session Moderator: R. Balfour Sartor (Chapel Hill, USA)

11:00 - 11:30 am MATERNAL MICROBIOME SHAPING THE IMMUNE SYSTEM OF INFANT Kathy McCoy (Calgary, Canada)

11:30 - 12:00 pm LONG TERM CONSEQUENCES OF EARLY LIFE IMPRINTING BY THE GUT MICROBIOTA Gérard Eberl (Paris, France)

12:00 - 12:30 pm MICROBIOME MODULATION OF IMMUNE SYSTEM IN IBD Harry Sokol (Paris, France)

12:30 - 02:00 pm Networking Lunch WORKSHOPS SESSION

02:00 - 03:30 pm WORKSHOPS 1, 2A, 3A & 5A 1. FMT BEYOND C. difficile Moderator: Colleen R. Kelly (Providence, USA) FMT in IBD: Jessica Allegretti (Boston, USA) FMT in metabolic syndrome: Max Nieuwdorp (Amsterdam, The Netherlands)

2A. MICROBIOME ACROSS AGE Moderator: D. Brent Polk (Los Angeles, USA) Microbiome in early life: Moran Yassour (Jerusalem, Israel) Microbiome in elderly: Paul W. O’Toole (Cork, Ireland)

3A. NUTRITION IN GUT MICROBIOTA MODULATION Moderator: Francisco Guarner (Barcelona, Spain) Fermented foods, probiotics and prebiotics in the era of microbiome science: Kevin Whelan (London, United Kingdom) Effect of plant-based diet on gut microbiota: Hana Kahleova (Washington DC, USA)

5A. MICROBIOME AND GUT-BRAIN AXIS Moderator: Emeran A. Mayer (Los Angeles, USA) Gut-brain connection: John Cryan (Cork, Ireland) Serotonin and gut microbiota: Jonathan Lynch (Los Angeles, USA)

03:30 - 04:00 pm Afternoon Break

04:00 - 05:30 pm WORKSHOPS 2B, 3B, 4 & 5B 2B. MICROBIOME ACROSS AGE Moderator: D. Brent Polk (Los Angeles, USA) Microbiome in early life: Moran Yassour (Jerusalem, Israel) Microbiome in elderly: Paul W. O’Toole (Cork, Ireland)

3B. NUTRITION IN GUT MICROBIOTA MODULATION Moderator: Francisco Guarner (Barcelona, Spain) Fermented foods, probiotics and prebiotics in the era of microbiome science: Kevin Whelan (London, United Kingdom) Effect of plant-based diet on gut microbiota: Hana Kahleova (Washington DC, USA)

4. TIME TO FOCUS ON THE SMALL INTESTINE Moderator: Purna Kashyap (Rochester, USA) Dietary antigen: Alberto Caminero (Hamilton, Canada) Bile acid and small intestine microbiota: Gary D. Wu (Philadelphia, USA)

5B. MICROBIOME AND GUT-BRAIN AXIS Moderator: Emeran A. Mayer (Los Angeles, USA) Gut brain connection: John Cryan (Cork, Ireland) Serotonin and gut microbiota: Jonathan Lynch (Los Angeles, USA)

05:30 - 07:00 pm Networking Reception SUNDAY, MARCH 8

08:15 - 08:30 am DAY 2 KICKOFF Gail Hecht (Chicago, USA)

PLENARY SESSION 3 Microbiome - Drug interactions Session Moderator: Francisco Guarner (Barcelona, Spain)

08:20 - 08:50 am , DRUG METABOLISM BY GUT AND THEIR GENES — Emily Balskus (Cambridge, USA)

08:50 - 09:20 am THE INFLUENCE OF PROTON PUMP INHIBITORS AND OTHER COMMONLY USED DRUGS ON THE GUT MICROBIOME Rinse K. Weersma (Groningen, The Netherlands)

09:20 - 09:50 am IMPACT OF NON-ANTIBIOTIC DRUGS ON THE GUT MICROBIOTA Athanasios Typas (Heidelberg, Germany)

09:50 - 10:20 am MICROBIOME AND IMMUNE CHECKPOINT INHIBITOR EFFICACY Lisa Derosa (Paris, France)

10:20 - 10:50 am Morning Break

PLENARY SESSION 4 Moving microbiome to the clinic Session Moderator: Robert F. Schwabe (New York, USA)

10:50 - 11:50 am PROFILING OF HUMAN-MICROBE SYMBIOSIS; HOW FAR ARE WE FROM CLINICAL APPLICATIONS? Joël Doré (Paris, France)

11:50 - 12:20 pm GUT MICROBIOME AND COLORECTAL CANCER Michael Scharl (Zurich, Switzerland)

12:20 - 12:50 pm DESIGNING DIAGNOSTICS AND THERAPEUTICS FOR THE GUT MICROBIOME David Riglar (London, United Kingdom)

12:50 - 01:00 pm CLOSING REMARKS Gail Hecht (Chicago, USA)

01:00 pm Lunch for all attendees GMFH 2020 SPEAKERS AND CHAIRS THE Jessica Allegretti (USA) Fernando Azpiroz (Spain) Emily Balskus (USA) FACULTY Ran Blekhman (USA) Alberto Caminero (Canada) John Cryan (Ireland) 2020 Emily Davenport (USA) Lisa Derosa (France) Gérard Eberl (France) ESNM / AGA JOINT SCIENTIFIC COMMITTEE Colin Hill (Ireland) Hana Kahleova (USA) Giovanni Barbara (Italy) Gail Hecht (USA) Jonathan Lynch (USA) Joël Doré (France) Purna Kashyap (USA) Kathy McCoy (Canada) Francisco Guarner (Spain) Colleen R. Kelly (USA) Max Nieuwdorp (The Netherlands) Dirk Haller (Germany) Emeran A. Mayer (USA) Paul W. O’Toole (Ireland) Harry Sokol (France) D. Brent Polk (USA) David Riglar (United Kingdom) Hania Szajewska (Poland) R. Balfour Sartor (USA) Michael Scharl (Switzerland) Michael Trauner (Austria) Robert F. Schwabe (USA) Eran Segal (Israel) Gary D. Wu (USA) Athanasios Typas (Germany) Rinse K. Weersma (The Netherlands) Kevin Whelan (United Kingdom) Moran Yassour (Israel)

ALLEGRETTI Jessica Dr. Jessica Allegretti is an attending gastroenterologist at the Brigham and Women’s Hospital Crohn’s and Colitis Center, where she serves as the center’s Director of Clinical Trials as well as the hospital’s Fecal Transplant Program Director. Dr. Allegretti’s research focuses on the intestinal microbiome and the consequences of its derangement, with the goal of understanding the role dysbiosis plays in microbial associated diseases, specifically clostridium difficile infections (CDI) and inflammatory bowel disease (IBD). Additionally she has lead several clinical trials investigating the role of FMT in other chronic diseases including obesity and primary sclerosis cholangitis.

AZPIROZ Fernando Professor of Medicine, Autonomous University of Barcelona Consultant, Department of Digestive Diseases, University Hospital General Vall d’Hebron Barcelona, Spain

Fernando Azpiroz is currently Professor of Medicine and Consultant in Digestive Diseases at the University Hospital Vall d’Hebron, Autonomous University of Barcelona, Spain. He graduated from medical school at the University of Valladolid, Spain, in 1977, and trained at the San Carlos University Hospital, Madrid, and at the Mayo Clinic, Rochester Minnesota, where he received the Edward C. Kendall Award for Meritorious Research. In 1986 he joined the Vall d’Hebron Department of Digestive Diseases where he served as Chief of the Department from 2009 to 2019. Dr Azpiroz clinical practice develops in a large referral unit, and specifically GMFH 2020 SPEAKERS AND CHAIRS focuses on functional gut disorders. His research program investigates the origin Jessica Allegretti (USA) of gastrointestinal sensations. Dr Azpiroz has been distinguished with the Masters Fernando Azpiroz (Spain) Award in Gastroenterology for Clinical Research in Digestive Diseases, Research Emily Balskus (USA) Award of the International Group for the Study of Gastrointestinal Motility, Ran Blekhman (USA) Alberto Caminero (Canada) Research Scientist Award of the Functional Brain Gut Research Group, and Senior John Cryan (Ireland) Investigator-Clinical Science Award of the International Foundation for Functional Emily Davenport (USA) Gastrointestinal Disorder. At present Dr Azpiroz serves as Chairman of the Microbiota Lisa Derosa (France) Gérard Eberl (France) & Health Section, European Society of Neurogastroenterology and Motility. Colin Hill (Ireland) Hana Kahleova (USA) Jonathan Lynch (USA) Kathy McCoy (Canada) Max Nieuwdorp (The Netherlands) BALSKUS Emily Paul W. O’Toole (Ireland) Emily is originally from Cincinnati, Ohio, where she first became interested in David Riglar (United Kingdom) Michael Scharl (Switzerland) chemistry as a high school student. She graduated from Williams College in 2002 Eran Segal (Israel) as valedictorian with highest honors in chemistry. After spending a year at the Athanasios Typas (Germany) University of Cambridge as a Churchill Scholar in the lab of Prof. Steven Ley, she Rinse K. Weersma (The Netherlands) Kevin Whelan (United Kingdom) pursued graduate studies in the Department of Chemistry and Chemical Biology Moran Yassour (Israel) (CCB) at Harvard University, receiving her PhD in 2008. Her graduate work with Prof. Eric Jacobsen focused on the development of asymmetric catalytic transformations and their application in the total synthesis of complex molecules. From 2008– 2011 she was an NIH postdoctoral fellow at Harvard Medical School in the lab of Prof. Christopher T. Walsh. Her research in the Walsh lab involved elucidating and characterizing biosynthetic pathways for the production of small molecule sunscreens by photosynthetic bacteria. She also received training in and environmental microbiology as a member of the Microbial Diversity Summer Course at the Marine Biology Lab at Woods Hole during the summer of 2009.

Emily joined the CCB faculty in 2011 and is currently a Professor of Chemistry and Chemical Biology. She is also an Associate Member of the Broad Institute of Harvard and MIT, a Faculty Associate of the Microbial Sciences Initiative at Harvard, a member of the Harvard Digestive Diseases Center, and a member of the MIT Center for Microbiome Informatics and Therapeutics. Her independent research has been recognized with multiple awards, including the 2011 Smith Family Award for Excellence in Biomedical Research, the 2012 NIH Director’s New Innovator Award, and the 2013 Packard Fellowship for Science and Engineering. She was selected as one of MIT Technology Review’s 35 Innovators Under 35 in 2014 and in 2016 was named an HHMI-Gates Faculty Scholar.

BLEKHMAN Ran Ran Blekhman is a McKnight Land-Grand Professor at the University of Minnesota. Before joining the University of Minnesota in 2013, Dr. Blekhman was a Postdoctoral Associate working with Andrew G. Clark at Cornell University. He holds a Ph.D. in Human Genetics from The University of Chicago, where he worked with Yoav Gilad. The Blekhman Lab studies human genomic factors that control and interact with the microbiome. We utilize high-throughput genomics technologies and employ computational, statistical, machine learning, and population genetic analytical approaches, with the goal of understanding how the host genome controls our microbial communities, how the microbiome regulates host genes, and how this host-microbe crosstalk affects human disease.

CAMINERO Alberto His research has been focused on the role of bacterial metabolism of dietary proteins in the context of intestinal diseases. Gluten is a clinically relevant group of proteins for human health and disease. On one hand, it constitutes one of the most abundant protein sources in human diet, and on the other, a proportion of individuals with genetic predisposition who ingest gluten will develop a serious condition called celiac disease. During his PhD at the University of Leon (Spain), he has characterized the duodenal microbiota, the section of the intestine affected in celiac disease, and has shown that celiac patients have a different microbiota than healthy volunteers. He also determined that the human gastrointestinal tract harbours bacteria that metabolize gluten. This was a key finding, as gluten immunogenicity resides on the fact that it is not metabolized by human digestive enzymes. As a member of Elena Verdu lab during his Postdoctoral fellow at McMaster University (Canada), he demonstrated that intestinal microbiota interacts with dietary antigens in vivo, such as gluten and other immunogenic wheat proteins, and modify its antigenicity differentially, with high implications on gluten-related disorders. He also showed that microbes in the small intestine could activate an innate immunity in the host with implications in food sensitivities. He is currently an Assistant Professor at McMaster studying diet-microbe interactions of relevance in Inflammatory bowel disease.

CRYAN John Prof. John F. Cryan trained in Galway, Ireland, Melbourne, Australia, University of Pennsylvania, and The Scripps Research Institute, La Jolla before spending four years as a LabHead in Novartis in Basel Switzerland. He moved to University College Cork (UCC) in 2005. He rose the ranks and has been Professor & Chair, Dept. of Anatomy & Neuroscience since 2011. He is co-author of the bestselling “The Psychobiotic Revolution: Mood, Food, and the New Science of the Gut-Brain Connection”. He has received numerous awards including UCC Researcher of the Year in 2012; UCC Research Communicator of the Year 2017, the University of Utrecht Award for Excellence in Pharmaceutical Research in 2013. He also received a Research Mentor Award from the American Gastroenterology Association and the Tom Connor Distinguished Scientist Award from Neuroscience Ireland in 2017. He was elected a Member of the Royal Irish Academy in 2017 and was a TEDMED speaker in 2014. He was awarded an Honorary Doctorate from the University of Antwerp, Belgium in 2018. He is immediate Past-President of the European Behavioural Pharmacology Society. DAVENPORT Emily Emily R. Davenport is an Assistant Professor in the Department of Biology at Penn State University who is interested in understanding the relationship between humans and our microbiomes. Having long been interested in microbes, Dr. Davenport earned a Bachelor of Science degree with comprehensive honors in Bacteriology from the University of Wisconsin-Madison in 2007. She became familiar with genomic techniques while working at the microarray company Roche NimbleGen between 2007 and 2009. She merged her interests in bacterial and eukaryotic genomics during her PhD in Human Genetics, which she earned from the University of Chicago in 2014. She continued to explore the role between host genetics, the microbiome, and phenotype during a postdoc at Cornell University between 2014 and 2019, which included a year as a visiting postdoc at the Max Planck Institute for Developmental Biology between 2018 - 2019. Since fall 2019, she has lead a lab at Penn State interested in understanding how human gut microbiomes are determined and what role they have on human health and evolution.

DEROSA Lisa Dr L. Derosa, MD (cancer immunotherapy oncologist), PhD (tumor immunology and oncomicrobiome), Faculty Paris Sud, graduated in Medical Oncology from the School of Medicine of the University of Pisa (Italy). She started her scientific career in the Laurence Zitvogel laboratory at Gustave Roussy as PhD Student and she is currently leading the kidney cancer and lung cancer clinical and translational research in- between Dr Albiges’s department and Dr Zitvogel’ laboratory. She has been actively contributing to the field of kidney and lung cancer, immunology, immunotherapy and microbiota, and she brought together basic and translational research. Her expertise is mainly human and murine microbiota. The creative output is the use of tumor-bearing avatar mice with fecal microbial transplantation from cancer patients as predictive of resistance to cancer therapy. She have also led collaborative efforts with numerous research groups including those focused on oncomicrobiome, immunology, genitourinary cancers, and rare tumors throughout her career. She is taking part in Torino Lumiere and Oncobiome networks that explore the possibility to stimulate anticancer immunosurveillance by manipulating the microbiome in lung, melanoma, breast and colon cancer patients. She is the recipient of several awards and grants (including three ASCO Merit Awards in 2017 and 2018 and two ESMO Merit Awards in 2014 and 2018).

DORÉ Joël Joël is Research Director at INRA Micalis Institute “Food and Gut Microbiology for Human Health” (www.micalis.fr) and Scientific Director of MetaGenoPolis (www.mgps. eu), a pre-industrial demonstrator in quantitative and functional metagenomics of the national “Futures Investment” program. Gut microbial ecologist by training, Joël pioneered intestinal metagenomics towards food-microbe-host interactions as well as diagnostic applications. With > 30 years of academic research and > 220 publications (H Index 69), Joël aims to provide a better understanding of man-microbes symbiosis towards personalized preventive nutrition and precision medicine. Joël is laureate of the ERC-Advanced Homo.symbiosus ; co-founder and scientific advisor of www. maat-pharma.com, a startup company dedicated to provide safe and standardized microbiotherapy solutions for the reconstruction of host-microbes symbiosis in the context of programmed clinical interventions inducing dysbiosis. Member of the BoD of GMFH, he supports the www.gutmicrobiotaforhealth.com scientific web- platform.

EBERL Gérard Gérard has graduated, completed his PhD and postdocs as an immunologist, investigating antigens recognized by T cells, the biology of so-called innate T cells, and the role of lymphoid tissue inducer cells. This latter type of cells became a founding member of now the bigger family of innate lymphoid cells (ILCs), and the core of the research of his lab for the last 14 years. From his first day at the Institut Pasteur in Paris, he has extensively collaborated with microbiologists to investigate the cross-talk between the symbiotic microbiota, ILCs and lymphocytes, a cross-talk that is necessary to maintain homeostasis of the host and develop a balanced immune system. Deregulation of this cross-talk, his team has shown, leads to inflammatory pathology. They now include the nervous system in this dialogue as a powerful sensor of the environment and regulator of immune responses. He is particularly dedicated to demonstrate that microbes are an important element of our physiology. Furthermore, he believes that the immune system has to be analyzed using a holistic approach, in which the other systems of the organism also play a role in defense, and in which the immune system is not only designed for defense. With these concepts as working hypotheses, his aim is to develop new approaches to prevent the development of inflammatory pathologies.

GUARNER Francisco Dr. Francisco Guarner graduated in Medicine at the University of Barcelona in 1973, trained Gastroenterology and Hepatology at Hospital Clinic (Barcelona); obtained PhD degree at University of Navarra (Spain). He was Research Fellow at Royal Free Hospital (London, UK), King’s College Hospital (London, UK), and Wellcome Research Laboratories (Beckenham, UK). He is Consultant of Gastroenterology at the Digestive System Research Unit, University Hospital Vall d’Hebron (Barcelona, Spain). Chair of the Steering Committee of the International Human Microbiome Consortium (www. human-microbiome.org), member of the Scientific Committee of Gut Microbiota for Health Section of the European Society of Neurogastroenterology and Motility (www.gutmicrobiotaforhealth.com), and past member of the Board of Directors on the International Scientific Association for Probiotics and Prebiotics (isappscience. org). Co-author of 319 publications on original research or reviews (Web of Science), holds an h-index of 62. HALLER Dirk Technical University of Munich, Chair of Nutrition and Immunology Director ZIEL Institute for Food & Health www.nutrition-immunology.de

The main areas of research of Prof. Haller are dedicated to the understanding of microbe-host interactions in the digestive tract. Nutrition and the intestinal microbiome play a pivotal role in the development of complex pathologies and a key question of Prof. Haller and his team is how these intestinal milieu factors modulate inflammatory and tumorigenic responses. The intestinal epithelium provides a dynamic interface to sense the metabolic and microbial environment in the gut and the unfolded protein response is a prime target of his research activities. In the past years, Prof. Haller and his team generated a comprehensive and conclusive understanding how complex microbial communities and specific mechanisms of microbe-host interactions affect chronic inflammation and tumor development using novel germ-free and gnotobiotic models. In addition, and most importantly to implement translational research, human intervention trials support the mechanistic studies in models and aim at defining the functional relevance of microbiome signatures in healthy populations (prospective cohort KORA and infants) and patients (IBD and colon cancer). In the past years, Prof. Haller established comprehensive research program at the national (DFG) Priority Program SPP 1656, and local level (DFG Collaborative Research Center CRC 1371; ZIEL Institute for Food & Health) to unravel the role of the gut microbiome in health and disease. Prof. Haller published 170 publications in international journals (h-index 47, Scopus; ranked 1% most cited scientists).

HECHT Gail Dr. Hecht is Professor of Medicine and Microbiology/Immunology and served as Chief, Gastroenterology and Nutrition at Loyola University Medical Center until July 2019. She earned her MD from Loyola University Stritch School of Medicine, completed Internal Medicine Residency at the University of Minnesota, Minneapolis, and her Fellowship in Gastroenterology at Brigham and Women’s Hospital, Harvard Medical School. Her initial faculty appointment was at the University of Illinois Chicago where she rose through the ranks to Professor and was appointed Chief of Digestive Diseases and Nutrition. She relocated to Loyola in January 2013. She serves as Editor-in-Chief of the journal Gut Microbes published by Taylor & Francis Group. Dr. Hecht has been very active in the American Gastroenterological Association functioning as Chair of the Intestinal Disorders Section of the AGA Council, as Basic Research Councilor to the Governing Board and ultimately serving as President from 2009-2010, only the second woman to serve in that capacity. HILL Colin Colin Hill has a Ph.D in molecular microbiology and is Professor of Microbial Food Safety in the School of Microbiology of University College Cork, Ireland. His main interests are in infectious disease, particularly in defining the mechanisms of virulence of foodborne pathogens and in developing strategies to prevent and limit the consequences of microbial infections in the gastrointestinal tract. He is particularly interested in the antimicrobial effects of probiotics, bacteriocins, and bacteriophage. He is also a Principal Investigator in APC Microbiome Ireland in Cork, a large research centre devoted to the study of the role of the gut microbiota in health and disease. In 2005 Prof. Hill was awarded a D.Sc by the National University of Ireland in recognition of his contributions to research. In 2009 he was elected to the Royal Irish Academy and in 2010 he received the Metchnikoff Prize in Microbiology and was elected to the American Academy of Microbiology. He has published more than 540 papers and holds 20 patents. He was president of ISAPP from 2012-2015.

KAHLEOVA Hana Dr. Kahleova is director of clinical research for the Physicians Committee for Responsible Medicine. She has conducted several clinical trials, using a plant-based diet in the treatment of obesity, diabetes, and metabolic disease. Her research showed that a plant-based diet leads to a greater weight loss and improvement in metabolism, and addresses multiple mechanisms behind diabetes.

Her research proved that eating a large breakfast and lunch is more beneficial than eating six smaller meals a day for patients with type 2 diabetes. Her research on meal frequency and timing showed that eating less frequently, no snacking, consuming breakfast, and eating the largest meal in the morning may be effective methods for preventing long-term weight gain.

As a member of the American Diabetes Association and as a board member of the Diabetes and Nutrition Study Group of the European Association for the Study of Diabetes, Dr. Kahleova is directly involved in the process of updating the nutritional recommendations for patients with diabetes.

KASHYAP Purna Dr. Purna Kashyap is an Associate Professor of Medicine, Physiology and Biomedical Engineering and the Co-Program Director of the Microbiome program in the Center for Individualized Medicine at Mayo Clinic, Rochester, MN. He is a fellow of the American Gastroenterology Association and member of their Center for Gut Microbiome Education and Research, and serves on the council of American Neurogastroenterology and Motility Society. He is the associate editor of Gut Microbes journal and serves on the editorial board of Neurogastroenterology and Motility and FASEB journal. Dr. Kashyap’s Gut Microbiome Laboratory is interested in understanding the complex interactions between diet, gut microbes, and gastrointestinal function. Deleterious alterations in gut microbiota have been associated with a number of disease states such as Clostridium difficile colitis, functional bowel disorders such as irritable bowel syndrome, and metabolic diseases such as obesity. However, the functional role of gut microbes in the development of these diseases remains largely unknown. To better understand the role of gut microbes, Dr. Kashyap’s laboratory integrates data generated from multi-omic platforms with in vivo and in vitro physiological measurements from human research participants and gnotobiotic mouse models to elucidate interactions among microbiota-derived bioactive molecules and the key regulators of gastrointestinal function. By combining experimental strategies with analysis, Dr. Kashyap’s research team hopes to develop novel microbiota-targeted therapies to treat patients with disorders resulting from altered microbiota function.

KELLY Colleen R. MD, FACG Associate Professor of Medicine Warren Alpert Medical School of Brown University The focus of Dr. Kelly’s research and clinical practice is Clostridium difficile infection (CDI) and fecal microbiota transplantation (FMT). She was the principal investigator (PI) for a first placebo-controlled trial of FMT for treatment of recurrent CDI and one of the first investigators to sponsor of an investigational new drug (IND) application for FMT with the Food and Drug Administration. She has since served on several working groups focusing on regulatory issues related to FMT. Dr. Kelly is currently site PI for an industry funded trial of live microbiota for treatment of recurrent CDI as well as investigator-initiated clinical trials assessing conventional FMT for CDI treatment. Dr. Kelly is interested in the long-term effects around manipulation of gut microbiota and serves as one of the PIs for an NIH-funded FMT National Registry which will answer important questions around the safety of FMT. She has collaborated on several studies investigating the impact of FMT on patients with Inflammatory Bowel Disease, Nonalcoholic Fatty Liver Disease and Alopecia Areata. In addition to coauthoring current FMT guidelines and participating in drafting the European Consensus Conference on Fecal Microbiota Transplant in Clinical Practice, she serves as the primary author for the forthcoming American College of Gastroenterology (ACG) 2019 C. difficile treatment guidelines. Dr. Kelly is a Fellow in the ACG and is a Fellow and past member of the scientific advisory board for Gut Microbiome Research and Education of the American Gastroenterological Association.

LYNCH Jonathan Jonathan was a National Science Foundation Graduate Research Fellow and received his PhD in Microbiology and Immunology from the Stanford University School of Medicine. He performed his thesis work in the lab of Dr. Justin Sonnenburg, where he studied how an abundant class of signaling proteins, the hybrid two-component systems, governed nutrient sensing in the gut microbiota. He was then a National Institutes of Health Ruth L. Kirschstein postdoctoral fellow in the lab of Dr. Ned Ruby at the University of Hawaii, where he leveraged the model squid-Vibrio symbiosis to study how mutualistic bacteria sense and respond to their host environment through membrane modifications and regulated motility. He recently started a position as an assistant project science in the lab of Dr. Elaine Hsiao at the University of California-Los Angeles, where he is studying the interactions between gut bacteria and the regulation of serotonin in the mammalian intestine.

MAYER Emeran A. Emeran A Mayer is Professor in the Departments of Medicine, Physiology and Psychiatry at the David Geffen School of Medicine at UCLA. He is the Executive Director of the G Oppenheimer Center for Neurobiology of Stress & Resilience and the co-director of the CURE: Digestive Diseases Research Center at UCLA. As one of the pioneers and leading researchers in the role of mind-brain-gut interactions in health and chronic disease, he has made major scientific contributions to the area of basic and translational enteric neurobiology with wide-ranging applications in clinical GI diseases and disorders. He has published more than 300 scientific papers (h-factor 111), and co edited 3 books, and his bestselling book The Mind Gut Connection has been published by Harper&Collins in 2016 and has been translated into 12 languages.

MC COY Kathy Dr. Kathy McCoy is a Professor in the Department of Physiology and Pharmacology, Cumming school of Medicine, and the Scientific Director of the International Microbiome Center at the University of Calgary, Canada. Her research group uses germ-free and gnotobiotic models to investigate the cellular and molecular mechanisms by which the microbiome regulates host immunity and physiology. She is particularly interested in the dynamic interplay between the gut microbiota and the innate and adaptive immune systems. Her research aims to understand how exposure to intestinal microbes, particularly during early life, educates and regulates the mucosal, systemic and neuronal immune systems and how this can affect susceptibility to diseases, such as allergy, autoimmunity, and neurodevelopmental disorders. Her lab also investigates how the microbiome regulates the immune system throughout life with the aim to identify microbial therapies that can be employed to enhance current therapeutic approaches, such as in cancer. O’TOOLE Paul W. School of Microbiology and APC Microbiome Ireland, University College Cork, Ireland.

Paul O’Toole is Professor of Microbial Genomics and head of the School of Microbiology at University College Cork, Ireland. He is a Principal Investigator in the APC Microbiome Institute (apc.ucc.ie). His main research theme is the metagenomics of gastrointestinal bacteria in humans, with emphasis on lactobacillus genomics, gut microbiota in ageing, colorectal cancer and in IBS. He has co-ordinated and participated in several major projects that examine the composition and function of the gut microbiota, its reaction to habitual diet, and its relationship to health, functional gastrointestinal disorders, and ageing. The ultimate aim is to understand and manipulate host-microbiome interactions, especially in the context of multi- factorial disease. He co-ordinated the ELDERMET project (eldermet.ucc.ie) that established diet-microbiota health interactions in 500 elderly persons, ELDERFOOD that investigated novel dairy ingredients for healthy aging, a recent APC prebiotic intervention in the elderly, and the microbiome analysis of the EU project NuAge, that investigated the effect of a Mediterranean diet on the microbiome and health of 600 older subjects across Europe. He has participated in multiple other EU projects. Research in his lab is supported by Science Foundation Ireland, Dept. Agriculture Fisheries and Marine, the Health Research Board, various APC industry partners, and the European Union.

POLK D. Brent Professor of Pediatrics Pediatric Gastroenterology, Hepatology & Nutrition Professor of Biochemistry & Molecular Medicine Vice Dean for Child Health - USC University of Southern California and Children’s Hospital Los Angeles Brent Polk is Professor of Pediatrics and Biochemistry & Molecular Medicine and vice dean for child health at the Keck School of Medicine of University of Southern California (USC). He is the former chair of the Department of Pediatrics for USC and past chief of pediatrics, physician-in-chief and vice president for academic affairs and director of the Saban Research Institute at Children’s Hospital Los Angeles (CHLA). A distinguished investigator, clinician and educator, Dr. Polk has more than 25 years of experience as a pediatric physician-scientist focused on the care of patients with inflammatory bowel disease (IBD), with the goal of asking questions through laboratory investigations – informed by patient care challenges – that may be translated back to identify risks of disease and targets for prevention or treatment. His laboratory is focused on the regulation of growth and development of the intestinal cell as it relates to development and disease, with a particular focus on signal transduction mechanisms in IBD. He currently serves as the Chair of the National Scientific Advisory Committee of the Crohn’s & Colitis Foundation and Chair of the Gastrointestinal Mucosal Pathobiology Study (GMPB) Study Section of the NIH. RIGLAR David David Riglar recently started a laboratory in the Department of Infectious Disease at Imperial College London, funded by a prestigious Sir Henry Dale Fellowship from the Wellcome Trust and Royal Society. His lab’s research aims to develop engineered bacteria as tools to probe and manipulate the mammalian gut microbiota. Using these tools together with imaging and sequencing based approaches, he is particularly interested to understand how the bacteria that comprise the mammalian gut microbiota vary their function spatially within the gut during inflammatory disease conditions. David undertook his postdoc at Harvard Medical School as an NHMRC/ RG Menzies and Human Frontier Science Program fellow with Pam Silver and his PhD as a Pratt Foundation Scholar at the Walter and Eliza Hall Institute, Australia with Jake Baum and Alan Cowman.

SCHARL Michael Dr Michael Scharl obtained his medical degree from the University of Regensburg in Germany and followed with two years of post-doctoral research at UC San Diego, Division of Gastroenterology. Dr Scharl is endowed Peter Hans Hofschneider Professor for Molecular Medicine, Head of Research, Senior Physician, Faculty Member and Lecturer in Gastroenterology at the University Hospital Zurich and University of Zurich. His research focuses on innate and adaptive immune responses in the pathogenesis of intestinal inflammation and intestinal carcinomas with the aim of achieving a better understanding of the complex interplay between genetic predispositions, intestinal microbiota and aberrant immune responses in the development of diseases.

SEGAL Eran Eran Segal is a Professor at the Department of Computer Science and Applied Mathematics at the Weizmann Institute of Science, heading a lab with a multi- disciplinary team of computational biologists and experimental scientists in the area of Computational and Systems biology. His group has extensive experience in machine learning, computational biology, probabilistic models, and analysis of heterogeneous high-throughput genomic data. His research focuses on Microbiome, Nutrition, Genetics, and their effect on health and disease. His aim is to develop personalized nutrition and personalized medicine. Prof. Segal published over 140 publications, and received several awards and honors for his work, including the Overton prize, awarded annually by the International Society for Bioinformatics (ICSB) to one scientist for outstanding accomplishments in computational biology, and the Michael Bruno award. He was recently elected as an EMBO member and as a member of the young Israeli academy of science. Before joining the Weizmann Institute, Prof. Segal held an independent research position at Rockefeller University, New York. Prof. Segal was awarded a B.Sc. in Computer Science summa cum laude in 1998, from Tel-Aviv University, and a Ph.D. in Computer Science and Genetics in 2004, from Stanford University. Lab website: http://genie.weizmann.ac.il

SOKOL Harry Harry Sokol, is Professor in the Gastroenterology department of the Saint Antoine Hospital (APHP, Paris, France), the co-director of the Microbiota, Gut & Inflammation team (INSERM CRSA UMRS 938, Sorbonne Université, Paris) and group leader in Micalis institute (INRA). Harry Sokol is an internationally recognized expert in Inflammatory Bowel Disease (IBD) and in gut microbiota fields. He published over 180 papers on these topics in major journals (including Gut, Gastroenterology, Cell Metabolism, Cell Host & Microbe, Nature communication, Nature Medicine). His work on the role of the gut microbiota in IBD pathogenesis led to landmark papers describing the IBD-associated dysbiosis (imbalance in gut microbiota composition) and the role of the pivotal commensal bacteria Faecalibacterium prausnitzii in gut homeostasis and in IBD. Currently, his work focuses on deciphering the gut microbiota-host interactions in health and diseases (particularly IBD), in order to better understand their role in pathogenesis and develop innovative treatments. Harry Sokol is exploring particularly the role of the microbiota in tryptophan metabolism for which he is recipient of an ERC grant. Beside basic science, he is also involved in translational research. He is the current president of the French group of fecal microbiota transplantation, he coordinated a pilot randomized control trial evaluating fecal microbiota transplantation in Crohn’s disease and he is currently coordinating a phase III nationwide randomized control trial evaluating fecal microbiota transplantation in ulcerative colitis. Homepage: https://sites.google.com/site/harrysokol/ Twitter: @h_sokol

TYPAS Athanasios Athanasios (Nassos) Typas is a trained biochemist, geneticist, and systems biologist. He leads a group at the Genome Biology Unit at EMBL, Heidelberg, Germany since 2011. His group combines systems microbiology with molecular mechanism to study bacterial cellular networks, and how bacteria interact with each other, the environment and the host. A key focal area of the group is on drug-microbe interactions: identifying new therapeutic strategies, understanding and predicting the drug mode of action and cellular resistance potential, and dissecting the interplay of medication with the gut microbiome. Nassos has received a number of awards (NIH K99/R00, Sofja Kovalevskaja Award- Humboldt Foundation, ERC consolidator grant) and is a member of the European Academy of Microbiology. WEERSMA Rinse K. Gastroenterologist, Head of the Department, Full Professor, Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Netherlands

CURRENT POSITIONS 2016-now: Chair of the Department of Gastroenterology and Hepatology University Medical Centre Groningen, Groningen, the Netherlands 2015- now Co-Chair Groningen Institute on Gastro Intestinal Genetics and Immunology (3GI) 2013-now Full Professor “Complex immune mediated gastrointestinal diseases” University of Groningen and University Medical Centre Groningen, PREVIOUS POSITIONS-2015: Visiting Scientist Harvard Medical School, Massachusetts General Hospital, Boston USA and the Broad Institute Cambridge, USA.

WHELAN Kevin Kevin Whelan is the Professor of Dietetics and Head of the Department of Nutritional Sciences at King’s College London. He is a Principal Investigator leading a research programme exploring the interaction between diet, the gastrointestinal microbiota and health and disease. He has undertaken numerous multi-centre investigations of the microbiota in patients with inflammatory bowel disease, irritable bowel syndrome and patients receiving artificial nutrition, and the use of diet to modify these. He has published over 150 peer-reviewed papers on the topics of fibre, probiotics, prebiotics and FODMAPs. He is the Series Editor of the ‘‘Advanced Nutrition and Dietetics’’ Book Series consisting of four books (Gastroenterology, Diabetes, Obesity, Nutrition Support). In 2012 he was awarded the Nutrition Society Cuthbertson Medal for clinical nutrition, in 2017 was appointed a Fellow of the British Dietetic Association and in 2018 delivered the Dr Elsie Widdowson Memorial Lecture.

YASSOUR Moran Dr. Moran Yassour is a senior lecturer at the Hebrew University, Faculty of Medicine, with joint affiliation at the school of Computer Science and Engineering. The Yassour lab studies the development of the human microbiome in health and disease, by developing new cohorts to study the establishment of the newborn gut microbiome and characterize the mother-to-child bacterial transmission. Moran recently finished her postdoctoral training at the Broad Institute of MIT and Harvard University, with Ramnik Xavier and Eric Lander, where she studied the human gut microbiome. During her PhD in the Friedman (HebrewU) and Regev (MIT/Broad) labs, she developed tools to reconstruct the transcriptome of partially assembled genomes and aberrant cancer genomes. Moran received her B.Sc., M.Sc., and Ph.D. in computer science and computational biology from the Hebrew University of Jerusalem.

OFFICIAL PCO

45 rue de Lourmel • 75015 Paris • France Phone: +33 1 83 63 70 21 www.cometotheworld.fr

CONGRESS INFORMATION / SPONSORSHIP ENQUIRIES [email protected]

GENERAL COORDINATION & PRODUCTION Farid Chabéni Email: [email protected] - Phone: +33 6 60 56 61 30

LOGISTICAL COORDINATION & REGISTRATION ENQUIRIES Lony Castans Email: [email protected] - Phone: +33 6 24 05 28 22 COME TO THE WORLD 2020

2020

The Gut Microbiota For Health World Summit is a scientific event sponsored by the European Society for Neurogastroenterology & Motility (ESNM) and the American Gastroenterological Association (AGA), with the endorsement of the American Neurogastroenterology and Motility Society (ANMS).